Relapsed or Refractory Diffuse Large B-Cell Lympho

Relapsed or Refractory Diffuse Large B-Cell Lympho | Norton Healthcare

As we continue to seek to protect our patients, face masks are required in patient settings such as hospitals, doctors’ offices and medical centers.

Indication: Relapsed or Refractory Diffuse Large B-Cell Lympho

A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of
Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Sub-indication: Hematological Malignancies

Study Type: Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: Sponsor: Merck & Co., Inc

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.

As we continue to seek to protect our patients, face masks are required in patient settings such as hospitals, doctors’ offices and medical centers.

Relapsed or Refractory Diffuse Large B-Cell Lympho Clinical Trial

Schedule an Appointment